Jefferies analyst Matthew Stanton lowered the firm’s price target on Repligen (RGEN) to $142 from $152 and keeps a Hold rating on the shares. Q1 was “enough” against a bar that had come down and order commentary was “encouraging,” the analyst tells investors in a post-earnings note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGEN:
- Repligen raises FY26 EPS view to $1.97-$2.05 from $1.93-$2.10, consensus $1.97
- Repligen reports Q1 adjusted EPS 48c, consensus 38c
- RGEN Upcoming Earnings Report: What to Expect?
- Repligen price target lowered to $145 from $165 at Canaccord
- Apple upgraded, Qualcomm downgraded: Wall Street’s top analyst calls